cip2 Antibody

What is CIP2A and why is it significant in research?

CIP2A functions as an inhibitor of protein phosphatase PP2A and plays a crucial role in oncogenesis. It promotes anchorage-independent cell growth and tumor formation by preventing dephosphorylation of MYC, thereby stabilizing MYC in human malignancies . Additionally, CIP2A works with TOPBP1 to respond to genome instability from acentric chromosome fragments in micronuclei, a phenomenon frequently observed in cancer cells . Given its overexpression in several cancer types, including colon, gastric, and breast cancers, CIP2A represents an important biomarker and potential therapeutic target in cancer research .

What types of CIP2A antibodies are commercially available?

There are several types of CIP2A antibodies available for research, with the most common being:

• Rabbit polyclonal antibodies: These recognize multiple epitopes within the CIP2A protein, such as those within the C-terminus region (aa 850 to C-terminus)

• Mouse monoclonal antibodies: These include specific clones like HL1925 that offer high specificity for human CIP2A protein

• Conjugated antibodies: Available with various tags including HRP, FITC, and multiple Alexa Fluor conjugates for direct detection in different applications

What are the primary applications for CIP2A antibodies?

CIP2A antibodies are validated for multiple applications including:

• Western blotting (WB): For detection of CIP2A protein in cell and tissue lysates

• Immunoprecipitation (IP): For isolation and enrichment of CIP2A protein complexes

• Immunohistochemistry (IHC-P): For detection of CIP2A in formalin-fixed, paraffin-embedded tissues

• Immunofluorescence (IF): For subcellular localization studies of CIP2A protein

• Immunocytochemistry (ICC): For detection in cultured cells

What are the optimal conditions for Western blotting with CIP2A antibodies?

For optimal Western blotting results with CIP2A antibodies:

• Recommended concentration: 0.04 μg/mL for rabbit polyclonal antibodies has been validated in multiple cell lines

• Expected band size: The predicted molecular weight is approximately 102 kDa

• Sample preparation: Total protein lysates should be prepared with RIPA buffer containing protease and phosphatase inhibitors

• Loading amount: 50 μg of whole cell lysate has been successfully used in published studies

• Detection method: Chemiluminescence using appropriate HRP-conjugated secondary antibodies and substrates like Immobilon Crescendo Western HRP substrate

• Exposure time: Short exposures (approximately 10 seconds) are often sufficient for detection

How should I perform immunohistochemistry with CIP2A antibodies?

For successful IHC with CIP2A antibodies:

• Antigen retrieval: Heat-induced epitope retrieval in pH9 EDTA-based buffer is recommended

• Primary antibody dilution: Rabbit polyclonal antibodies can be used at 1/200 (1 μg/ml) , while the optimal range for different antibodies may be 1:20-1:200

• Detection system: Use appropriate anti-Ig horseradish peroxidase-conjugated polymer (e.g., Flex+, Dako)

• Visualization: 3,3′-diaminobenzidine (DAB) is commonly used as a chromogen

• Controls: Include negative controls (non-immunized rabbit immunoglobulins) and positive controls (known CIP2A-expressing breast tumor sections)

What species reactivity can I expect with CIP2A antibodies?

CIP2A antibodies show reactivity with multiple species:

• Human: Validated in multiple human cancer cell lines including HEK-293T, HepG2, MCF7, and HeLa

• Mouse: Confirmed reactivity in mouse cell lines such as CT26 (colon carcinoma), NIH/3T3 (embryo fibroblast), CH27 (B cell lymphoma), and TCMK-1 (kidney epithelial)

• Rat: Validated in cell lines like C6 (glial tumor)

How does CIP2A expression correlate with AKT phosphorylation in cancer?

CIP2A expression strongly correlates with AKT phosphorylation in cancer:

How can I design antibodies with customized specificity profiles for CIP2A research?

Designing antibodies with customized specificity involves:

• Biophysics-informed modeling: Train computational models on experimentally selected antibodies to identify distinct binding modes associated with specific ligands

• Phage display selection: Conduct phage display experiments with antibody libraries against various combinations of ligands to generate training data

• Energy function optimization: For cross-specific antibodies, jointly minimize the energy functions associated with desired ligands; for specific antibodies, minimize functions for desired ligands while maximizing those for undesired ligands

• Validation: Test predicted antibody variants experimentally to confirm specific or cross-specific binding properties

• CDR3 variation: Focus on varying complementarity determining regions, particularly CDR3, as these regions are critical for antibody specificity

What is the biological significance of CIP2A in cancer progression?

CIP2A plays several crucial roles in cancer progression:

What controls should I include when working with CIP2A antibodies?

Proper experimental controls for CIP2A antibody work include:

• Positive controls: Use cell lines known to express CIP2A such as HEK-293T, HepG2, MCF7, or HeLa for Western blotting

• Negative controls: Include control IgG for immunoprecipitation experiments

• Validation controls: For IHC, include sections incubated with non-immunized rabbit immunoglobulins as negative controls

• Knockdown verification: siRNA-mediated CIP2A knockdown can serve as specificity controls in functional studies

• Dilution series: For antibody optimization, test a range of concentrations (e.g., 1:20-1:200 for IHC)

How can I optimize transfection conditions for CIP2A knockdown or overexpression studies?

For effective transfection in CIP2A studies:

• Cell seeding: Plate breast cancer cells in 6-well plates at appropriate density for 60-80% confluence at transfection

• Transfection reagent: 10 μL of Lipofectamine 2000 has been successfully used for breast cancer cell lines

• siRNA concentration: 75 nM of CIP2A-specific siRNAs is effective for knockdown studies

• Plasmid amount: 1 μg of plasmidic vectors is suitable for overexpression experiments

• Validation: Confirm knockdown or overexpression by Western blot using specific anti-CIP2A antibodies at 1:1000 dilution

• Controls: Include scrambled siRNA or empty vector controls to account for non-specific effects

What factors affect the sensitivity and specificity of CIP2A detection in clinical samples?

Several factors influence the reliability of CIP2A detection in clinical samples:

• Sample preparation: Paired fresh frozen and FFPE samples should be processed consistently

• Antibody validation: Confirm specificity through Western blot and IHC correlation in the same samples

• Antigen retrieval method: Optimization of pH and buffer composition affects epitope accessibility

• Antibody dilution: Sensitivity can be optimized by testing a range of dilutions (CIP2A: 1:20-1:200, p-AKT: 1:1-1:100)

• Detection system: Choose appropriate secondary antibodies and detection methods for the application

• Scoring system: Develop consistent scoring criteria for positivity in immunohistochemistry to ensure reproducibility

How might CIP2A antibodies be used in precision medicine approaches?

CIP2A antibodies have potential applications in precision medicine:

• Biomarker development: CIP2A overexpression is associated with specific cancer subtypes and can serve as a prognostic marker

• Treatment stratification: Since CIP2A correlates with HER2 positivity and triple-negative breast cancer, it may help identify patients likely to respond to certain therapies

• Therapeutic targeting: As CIP2A plays a role in AKT signaling and tumor progression, antibodies could be developed for therapeutic applications

• Monitoring response: CIP2A expression levels might be monitored to assess treatment efficacy

• Companion diagnostics: CIP2A antibodies could be incorporated into companion diagnostic assays for emerging targeted therapies